PVPablo Vega

Pablo Vega

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pablo Vega has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Building a Brief Multidomain Questionnaire for Gambling Dual Disorder: Psychometric Validation and RDoC‐Based Dimensional Structure

    by Ignacio Basurte‐Villamor, Ismael Gomez‐Talal, Pablo Vega, Mana Azizsoltani, Javier Gonzalez‐Peñas, Francisco Ferre, Nestor Szerman

    Objectives: Gambling Disorder (GD) frequently co‐occurs with other mental disorders, a clinical condition termed Gambling Dual Disorder (GDD) that is often overlooked. We aimed to develop and validate a brief multidomain questionnaire to assess GDD severity within a dimensional, transdiagnostic framework. Methods: A 55‐item questionnaire was developed and tested across three phases (feasibility, reliability, validity) in 30, 57, and 223 treatment‐seeking adults with DSM‐5‐TR GD. We assessed internal consistency, test–retest reliability, convergent validity against reference instruments (STAI, BDI‐II, ISI, BIS, CAARS, SPIN, MULTICAGE‐CAD‐4, TCI‐R, SDI), ROC‐derived cutoffs, and the latent dimensional structure via exploratory and confirmatory factor analyses, mapped onto the NIMH Research Domain Criteria (RDoC). Results: Internal consistency was excellent ( α = 0.93); test–retest reliability was moderate (ICC = 0.29–0.62). Convergent validity was strong ( r ≈ 0.51–0.72). ROC‐based cutoffs prioritized sensitivity, with negative predictive values generally above 0.80. A global severity threshold near 1.44 enabled clinical stratification. A four‐factor structure emerged: emotional distress and gambling impairment, impulsivity and behavioral activation, social anxiety and interpersonal suspiciousness, and executive dysfunction with negative self‐perception. Conclusion: The instrument is a reliable, valid, RDoC‐aligned tool for stratifying GDD severity and tailoring integrated interventions.

  • Open Access

    Is there a risk of esketamine misuse in clinical practice?

    by Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman, Marta Torrens, Pablo Vega, Pilar Andres-Olivera, Francisco Javier Álvarez

    In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine’s dosing guidelines and strict medical supervision stem from prior research on ketamine’s use in depression and history as a recreational drug. Despite initial concerns, long-term clinical studies have not documented instances of abuse, misuse, addiction or withdrawal, and the same was found in case reports or subsamples of high-risk populations with comorbidities such as substance use disorder or alcohol use disorder. Esketamine has proven to be safe and well tolerated without fostering new-onset substance use in vulnerable groups. Real-world studies reinforced these observations, reporting no adverse events (AEs) related to pharmacological interactions of esketamine with any other substance, and no new-onset drug or alcohol misuse, craving, misuse or diversion of use. Reports of esketamine craving remain rare, with only one case report documented in 2022. Most drug-related AEs reported in pharmacovigilance databases are those identified in the product’s technical data sheet and with known reported frequency. More importantly, no register of illicit acquisition of esketamine or its tampering for obtaining ketamine or other altered products was found in our search. Overall, our review confirms esketamine’s safety across diverse patient populations, reassuring its responsible use and the scarcity of reports of abuse or misuse since its introduction to the market.


  • Open Access

    A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment

    by Ignacio Basurte-Villamor, Pablo Vega, Carlos Roncero, José Martínez-Raga, Lara Grau-López, Lourdes Aguilar, Marta Torrens, Nestor Szerman

    Background: Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortioxetine in clinical practice and determine its effect on affective symptoms, cognitive function, quality of life, and substance use in patients with MDD and SUD. Methods: Post-authorization, retrospective, multicenter, descriptive, and observational study in 80 patients with MDD and SUD receiving a maintenance treatment with vortioxetine for six months between January 2017 and April 2021. Results: Compared with baseline, scores significantly decreased after 3 and 6 months of treatment in the Montgomery-Åsberg Depression Rating Scale total (from 28.9 to 17.7 and 12.0), and global functional impairment of the Sheehan Disability Inventory (from 26.3 to 19.1 and 16.7). The number of correct answers in the symbol digit modalities test significantly improved during vortioxetine treatment (from 40.4 to 43.8 and 48.4). Regarding the clinical global impression scale, the score for disease severity significantly decreased from 3.8 to 3.0 and 2.4. Compared with baseline, there was a significant reduction in consumption of practically all substances, especially of alcohol, cannabis, and cocaine. Conclusion: Vortioxetine was effective in clinical practice for alleviating depressive symptoms and functional impairment, and in improving cognitive and executive functions and disease severity in patients with MDD and SUD. Moreover, the treatment with vortioxetine favored a reduction in substance use and the severity of the SUDs.


  • Open Access

    Results of a Hepatitis C Micro-Elimination Program in Two Addiction Centers Among Subjects With Substance Use Disorder

    by Pablo Vega-Astudillo, Ignacio Basurte-Villamor, Inés De Ema López, Ruth Olmos Espinos, Beatriz Mesías-Pérez, Nestor Szerman

    Objectives: We aimed to evaluate a hepatitis C (HCV) micro-elimination program in 2 addiction centers among subjects with substance use disorders (SUD). Methods: The program was based on simplifying the diagnosis of HCV infections by avoiding referral to primary care for the diagnosis and performing the necessary tests at the point of care (ie, the addition center) and simplifying the patient pathway by directly referring patients to the specialized care for treatment. Descriptive and multivariate analyses are presented. Results: Of the 1497 subjects included in the program, 327 reported that they were anti-HCV-positive. Among the 1170 patients who were offered the HCV rapid antibody test, 180 (15.4%) did not perform the test. Performing the HCV rapid antibody test only contributed ten patients (3%) to the 337 who were anti-HCV-positive. A high proportion (147 out of 327 [45%]) of subjects who reported being anti-HCV-positive also reported that they had not been treated for HCV. Among the 67 subjects who were HCV-RNA-positive and were referred for treatment, 53 (79%) ultimately received and completed antiviral treatment. Unfortunately, we did not find any factors associated with not performing dry blood testing, and the factors associated with not performing the HCV rapid antibody test were difficult to interpret, and the model showed low goodness of fit. Conclusions: Our results suggest that a micro-elimination program focused on patients with SUD attending an addiction center is not effective for screening the presence of hepatitis C but is successful for linking patients with hepatitis C to antiviral treatment.

  • Open Access

    Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

    by Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Arias

    A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a

  • Open Access

    Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study

    by Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Arias

    Aim To evaluate the efficacy and impact of long-acting injectable (LAI) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (SUD). Patients and methods A multicenter, observational, descriptive and retrospective study was conducted in patients with a DSM-5 diagnosis of schizophrenia who had a coexisting SUD and were treated with LAI-aripiprazole. Disease severity was evaluated with the Clinical Global Impression (CGI) severity scale for schizophrenia, daily functioning and disability were evaluated with the World Health Organisation Disability Assessment Scale (WHODAS-2.0), and the severity of the addiction was evaluated with the Severity of Dependence Scale (SDS). Results The sample included 40 patients. Overall, after 6 months of treatment with LAI-aripiprazole at a dose of 400 mg/4 weeks in 77.5% of the patients, we observed significant improvement in the psychopathological symptoms, with a reduction of over 30% in the scores of the five CGI-severity scales. The WHODAS-2.0 mean (standard deviation) score was also significantly reduced from 57.6 (8.2) to 42.3 (4.3) points (p < 0.001). Regarding SUDs, after 6 months of treatment, substance use was stopped in 5 of the 9 patients with cocaine use disorder and in 3 of the 16 patients with alcohol abuse disorder. A significant reduction in the severity of the dependence was observed only in the subgroups of participants with cocaine and alcohol use disorders. Conclusion Our study suggests that once-monthly LAI-aripiprazole retains its antipsychotic efficacy in patients with schizophrenia and a coexisting SUD and could be useful for the management of cocaine or alcohol use disorders in this population.